Apimeds Pharmaceuticals US, Inc.
APUS· NYSE
APUSApimeds Pharmaceuticals US, Inc.
Who holds Apimeds Pharmaceuticals US, Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Hemenway Trust Co LLC | 274K | ±0% | $246.6K | 0.1% | Aug 11, 2026 |
| Vanguard Capital Management LLC | 63.7K | −33.6% | $57.3K | 0% | Aug 13, 2026 |
| Geode Capital Management, LLC | 35.1K | −12.3% | $31.6K | 0% | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 24K | ±0% | $21.6K | 0% | Aug 13, 2026 |
| Jane Street Group, LLC | 16K | New | $14.4K | 0% | Aug 14, 2026 |
| UBS Group AG | 11.8K | +182.3% | $10.6K | 0% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 1.7K | New | $1.5K | 0% | Aug 11, 2026 |
